NCT01937299View on ClinicalTrials.gov

Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®

PHASE4CompletedINTERVENTIONAL
Enrollment

307

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Ocular HypertensionOpen Angle Glaucoma
Interventions
DRUG

Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension

DRUG

Vehicle

Inactive ingredients used as a placebo comparator

DRUG

Travoprost 0.004% ophthalmic solution

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT01937299 - Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z® | Biotech Hunter | Biotech Hunter